Physician profile
Moses C Ejiofor
NPI 1942277843
$6,439.66
in general payments reported to CMS, 2019-2025
23 companies · $1,159 in 2025
The $1,159 reported for 2025 was more than what 81% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $673 · 2020: $416 · 2021: $878 · 2022: $996 · 2023: $1,308 · 2024: $1,010 · 2025: $1,159.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,351 · Education: $126.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,350.57 |
| Education | $126.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,183.91 | 2020-2025 | Krystexxa, Tavneos |
| Horizon Therapeutics Plc | $1,121.79 | 2019-2023 | Krystexxa |
| Glaxosmithkline, LLC. | $755.73 | 2020-2024 | Benlysta |
| Travere Therapeutics, INC. | $605.09 | 2023-2025 | Filspari |
| Astrazeneca Pharmaceuticals Lp | $593.22 | 2019-2025 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $407.17 | 2021-2025 | |
| Vifor Pharma, INC. | $344.29 | 2019-2025 | Veltassa |
| Novartis Pharmaceuticals Corporation | $250.76 | 2023-2025 | |
| Ardelyx, INC. | $231.99 | 2024-2025 | Ibsrela |
| Calliditas Therapeutics US INC. | $176.64 | 2022-2025 | Tarpeyo |
| Mallinckrodt Enterprises LLC | $127.96 | 2019 | |
| Vantive US Healthcare LLC | $121.03 | 2025 | Renal - Pd |
| Fresenius USA Marketing, INC. | $88.45 | 2019-2021 | |
| Akebia Therapeutics INC | $80.86 | 2025 | Vafseo |
| Opko Pharmaceuticals, LLC | $75.99 | 2022-2025 | Rayaldee |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $72.70 | 2019 | |
| Genzyme Corporation | $43.22 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $41.87 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $41.25 | 2020-2023 | |
| Pfizer INC. | $32.94 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.63 | 2022 | |
| Alnylam Pharmaceuticals INC. | $14.70 | 2021 | |
| Allergan, INC. | $11.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Moses Ejiofor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.